Deal title |
Principal company |
Partner company |
Total projected at signing (US$M) |
Start date |
August | ||||
Amgen and Organovo to explore the utility of Exvive human liver tissue |
Amgen Inc. |
Organovo Holdings |
Payment Unspecified |
8/23/17 |
Cancer Research UK to develop Eli Lilly's LY-3143921 in an early stage trial for cancer |
Cancer Research UK |
Eli Lilly and Co. |
Unknown |
8/23/17 |
Medikine and Organovo to explore Exvive kidney tissue to study progression and reversal of fibrosis because of its multicellular nature |
Medikine Inc. |
Organovo Holdings |
Payment unspecified |
8/23/17 |
Mylan to commercialize Otsuka's delamanid for MDR-TB in South Africa and India |
Otsuka Novel Products GmbH |
Mylan Pharmaceuticals Inc. |
Payment unspecified |
8/24/17 |
Horus to distribute Alimera's Iluvien for diabetic macular edema in France |
Alimera Sciences Inc. |
Horus Pharma |
Payment unspecified |
8/29/17 |
Saol Therapeutics to acquire Winrho SDF, Hepagam B, and Varizig from Aptevo Therapeutics |
Aptevo Therapeutics Inc. |
Saol Therapeutics Inc. |
$74.50 |
8/31/17 |
Astrazeneca and Takeda to develop and commercialize MEDI-1341 for Parkinson's disease worldwide |
Astrazeneca plc |
Takeda Pharmaceutical Co. Ltd. |
$400.00 |
8/29/17 |
Camargo to provide regulatory consulting services for Lumosa's LT-1001 against pain in the U.S. |
Camargo Pharmaceutical Services |
Lumosa Therapeutics Co. Ltd. |
Payment unspecified |
8/28/17 |
Megapharm to distribute Emmaus Life Sciences' Endari (L-glutamine oral powder) in Israel and Palestine |
Emmaus Medical Inc. |
Megapharm Ltd. |
Payment unspecified |
8/30/17 |
FarmaUSA to distribute Isodiol's Isoderm for headaches, body and joint pain, and nervous system disorders in Brazil and across South America |
Isodiol International Inc. |
FarmaUSA |
Payment unspecified |
8/30/17 |
Asia Genomics to distribute Nanthealth's GPS Cancer in Southeast Asian countries |
Nanthealth Inc. |
Asia Genomics Pte. Ltd. |
Payment unspecified |
8/30/17 |
Servier and Philogen to discover small-molecule therapeutics for undisclosed indication |
Philogen SpA |
Servier |
Payment unspecified |
8/25/17 |
Megapharm to market Santhera Pharmaceuticals' Raxone against Leber's hereditary optic neuropathy in Israel |
Santhera Pharmaceuticals AG |
Megapharm Ltd. |
Payment unspecified |
8/31/17 |
Labcyte and Sengine to provide functional drug screening for oncology |
Sengine Precision Medicine |
Labcyte Inc. |
Unknown |
8/30/17 |
Dong-A ST and Takeda to sell and market Edarbi in Korea |
Takeda Pharmaceutical Co. Ltd. |
Dong-A ST Co. Ltd. |
Payment unspecified |
8/30/17 |
Variantyx and Fdna to integrate Genomic Intelligence platform with Face2gene technology to facilitate rare disease diagnosis |
Variantyx |
Fdna Inc. |
Payment unspecified |
8/30/17 |
Novartis to license gevokizumab and IP related to IL-1 beta targeting antibodies including canakinumab against cardiovascular diseases |
Xoma Corp. |
Novartis AG |
$31.00 |
8/25/17 |
September | ||||
Abcellera and GSK to identify the antibodies against an undisclosed membrane protein target using single cell antibody screening platform |
Abcellera Biologics Inc. |
Glaxosmithkline plc |
Payment unspecified |
9/12/17 |
GT Biopharma to use Accu-Break Pharmaceuticals' technology to develop Painbrake for neuropathic pain |
Accu-Break Pharmaceuticals Inc. |
GT Biopharma Inc. |
Payment unspecified |
9/11/17 |
Andarix and Wuxi Fortune to develop and commercialize Tozaride for lung and other cancers in China |
Andarix Pharmaceuticals Inc. |
Wuxi Fortune Pharmaceutical Co. Ltd. |
Payment unspecified |
9/6/17 |
Aplagon and Cadila to develop and commercialize the APAC product for the prevention of blood vessel occlusions |
Aplagon OY |
Cadila Pharmaceuticals (Sweden) AB |
Payment unspecified |
9/19/17 |
Taiho to receive a license option to Arcus' product candidates for cancer in Japan and certain other territories in Asia (excluding China) |
Arcus Biosciences Inc. |
Taiho Pharmaceutical Co. Ltd. |
$310.00 |
9/19/17 |
China National Bluestar and Asahi Kasei to form joint ventures for the mPPE business in China |
Asahi Kasei Corp. |
China National Chemical Corp. |
Unknown |
9/5/17 |
Aspen Global to acquire remaining rights for Astrazeneca's anesthetic medicines |
Aspen Global Inc. |
Astrazeneca plc |
$766.00 |
9/14/17 |
Axxam and Sanofi to optimize a lead series of small molecules for neurodegeneration |
Axxam SpA |
Sanofi SA |
Payment unspecified |
9/5/17 |
Cardiome to distribute Basilea's ceftobiprole in Europe and Israel |
Basilea Pharmaceutica International Ltd. |
Cardiome Pharma Corp. |
$5.25 |
9/12/17 |
Beijing Zhongyuan to distribute Genovis' products in Chinese market |
Beijing Zhongyuan Ltd. |
Genovis AB |
Payment unspecified |
9/18/17 |
Bayer to innovate and accelerate cell line development and antibody discovery using BLI's Beacon platform |
Berkeley Lights Inc. |
Bayer AG |
Payment unspecified |
9/12/17 |
Kamada and BGN to advance the research on mechanism of action of alpha-1 antitrypsin |
BGN Technologies |
Kamada Ltd. |
Payment unspecified |
9/6/17 |
Bioverativ and Bicycle to discover, develop and commercialize therapies for hemophilia and sickle cell disease |
Bicycle Therapeutics Ltd. |
Bioverativ Inc. |
$424.20 |
9/6/17 |
U.S. Worldmeds to commercialize Catalent's lofexidine against opioid withdrawal and facilitate completion of opioid discontinuation treatment in the U.S. |
Catalent Inc. |
US Worldmeds LLC |
Payment unspecified |
9/5/17 |
Biontech to license Cellscript's nucleoside-mRNA for use in all in vivo applications for treatment of cancer and other diseases |
Cellscript Inc. |
Biontech AG |
Payment unspecified |
9/6/17 |
CPE Funds and 3SBio to establish a joint venture as contract development and manufacturing platform in North America |
CITICPE |
3SBio Inc. |
Unknown |
9/1/17 |
Eisai and Ono to develop combination therapy of Lenvima and Opdivo against hepatocellular carcinoma |
Eisai Co. Ltd. |
Ono Pharmaceutical Co. Ltd. |
Payment unspecified |
9/8/17 |
Evotec and Abivax to discover and develop novel therapies for multiple viral infectious diseases |
Evotec AG |
Abivax |
Payment unspecified |
9/7/17 |
GGC and Fdna to evaluate GGC's patient data using Fdna's Face2gene |
Fdna Inc. |
Greenwood Genetic Center Inc. |
Payment unspecified |
9/6/17 |
Morphotek and Fujirebio Diagnostics to develop CA125 II assay as a companion diagnostic for farletuzumab against ovarian cancer patients |
Fujirebio Diagnostics Inc. |
Morphotek Inc. |
Payment unspecified |
9/5/17 |
Airway to use Glycotope's Glycoexpress for the production of AT-100 against bronchopulmonary dysplasia worldwide |
Glycotope GmbH |
Airway Therapeutics LLC |
Payment unspecified |
9/11/17 |
GMS and Tenshi to establish a joint venture, GMS Tenshi Holdings, to deliver biosimilars to emerging markets |
GMS Holdings |
Tenshi Life Sciences Pvt. Ltd. |
Unknown |
9/8/17 |
Boehringer Ingelheim and Gubra to develop therapeutic peptides for obesity |
Gubra Aps |
Boehringer Ingelheim Corp. |
$298.09 |
9/7/17 |
Undisclosed Japanese company to develop Hanall's new formulation of HL-036 for inflammatory ocular diseases and macular degeneration |
Hanall Biopharma Co. Ltd. |
Undisclosed |
Payment unspecified |
9/12/17 |
Harbour to develop and commercialize Hanall's HL-161 and HL-036 for autoimmune diseases, dry eye and other inflammatory diseases in China |
Hanall Biopharma Co. Ltd. |
Harbour Biomed |
$81.00 |
9/12/17 |
Cocrystal Pharma to discover novel chemical leads for multiple therapeutic targets using Hitgen's DNA-encoded library technology platform |
Hitgen Ltd. |
Cocrystal Pharma Inc. |
Payment unspecified |
9/5/17 |
Hitgen to discover novel small molecules for Takeda's multiple target therapeutic areas worldwide |
Hitgen Ltd. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
9/11/17 |
Allergan to use Lyndra's sustained-release technology to develop ultra-long-acting products for Alzheimer's disease |
Lyndra Inc. |
Allergan plc |
$105.00 |
9/7/17 |
Millennium Pharmaceuticals and Noile-Immune to develop new CAR-T cell immunotherapy against solid tumors |
Noile-Immune Biotech Inc. |
Millennium Pharmaceuticals Ltd. |
Payment unspecified |
9/4/17 |
Helsinn Therapeutics to copromote Novartis' Zykadia for cancer in U.S. |
Novartis AG |
Helsinn Therapeutics Inc. |
Payment unspecified |
9/5/17 |
GTH to develop Oncobiologics' ONS-1045 and ONS-3010 in emerging markets excluding China, India and Mexico |
Oncobiologics Inc. |
GMS Tenshi Holdings Pvt. Ltd. |
$7.50 |
9/8/17 |
Monopar to develop and commercialize Onxeo's Validive for oral severe mucositis worldwide |
Onxeo SA |
Monopar Therapeutics LLC |
$109.00 |
9/13/17 |
Ora to conduct phase II clinical study of Hanall's HL-036 for dry eye disease in U.S. |
Ora Inc. |
Hanall Biopharma Co. Ltd. |
Payment unspecified |
9/12/17 |
Gercor to conduct phase II combination study of OSE's Tedopi with a PD-1 checkpoint inhibitor against pancreatic cancer |
OSE Immunotherapeutics |
Gercor |
Payment unspecified |
9/6/17 |
Fosun Pharma to develop and commercialize Palatin's bremelanotide for female sexual dysfunction in China, Taiwan, Hong Kong and Macau |
Palatin Technologies Inc. |
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. |
$105.00 |
9/6/17 |
Phosplatin and Merck to evaluate PT-112 in combination with avelumab for cancer |
Phosplatin Therapeutics LLC |
Merck KGaA |
Payment unspecified |
9/9/17 |
Mei Pharma to develop and commercialize Presage's voruciclib against cancer worldwide |
Presage Biosciences |
Mei Pharma Inc. |
$183.90 |
9/5/17 |
Vectura to use Pulmatrix's PUR-0200 to develop VR410 for chronic obstructive pulmonary disease |
Pulmatrix Inc. |
Vectura Group plc |
$1.00 |
9/6/17 |
Puretech to license Calix milk derived exosome-based technology to 3P Biotechnologies |
Puretech Health plc |
3P Biopharmaceuticals |
Payment unspecified |
9/19/17 |
Petra and Schrodinger to develop therapeutics for cancer and metabolic diseases |
Schrodinger Inc. |
Petra Pharma Corp. |
Payment unspecified |
9/19/17 |
Avadel to develop and commercialize Serenity's Noctiva for disorders in voiding and control of urination including nocturia in the U.S. and Canada |
Serenity Pharmaceuticals |
Avadel Pharmaceuticals plc |
$290.00 |
9/1/17 |
Sphaera Pharma and Q Biomed to develop analog of QBM-001 for pediatric developmental nonverbal disorder |
Sphaera Pharma |
Q Biomed Inc. |
Payment unspecified |
9/19/17 |
Maruishi to develop and commercialize Sumitomo's FAAH inhibitor for nausea and vomiting |
Sumitomo Dainippon Pharma Co. Ltd. |
Maruishi Pharmaceutical Co. Ltd. |
Payment unspecified |
9/6/17 |
Synpromics to conduct research on Solid's gene therapy to develop new treatments for Duchenne muscular dystrophy |
Synpromics Ltd. |
Solid Biosciences LLC |
Payment unspecified |
9/20/17 |
TCL to manufacture galacto oligosaccharides using Optibiotix's LPGOS to reduce cardiovascular risk factors by using in food and OTC products |
Tata Chemicals Ltd. |
Optibiotix Health plc |
Payment unspecified |
9/5/17 |
CVC Capital Partners to purchase Teva's women's health portfolio products |
Teva Pharmaceutical Industries Ltd. |
CVC Capital Partners |
$703.00 |
9/18/17 |
Undisclosed joint venture company to acquire Therapure's contract development and manufacturing business and certain rights to plasma products and technology for the Chinese market |
Therapure Biopharma Inc. |
Undisclosed |
$290.00 |
9/1/17 |
Alvogen to market Vivus' Qsymia in the Republic of Korea for treatment of chronic weight management or weight-related conditions |
Vivus Inc. |
Alvogen Inc. |
Payment unspecified |
9/5/17 |
Zealand Pharma and Orbit Discovery to identify novel peptide therapeutics against gastrointestinal and metabolic diseases |
Zealand Pharma A/S |
Orbit Discovery |
Payment unspecified |
9/7/17 |
|
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. | ||||